Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Analysis of Population Pharmacokinetic Data

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Pharmacokinetic Models: Comparison and Selection Criterion

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Switching Biologics in Severe Asthma: Cautionary Lessons from NIMBLE.

American journal of respiratory and critical care medicine·2026

Same author

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry.

The Lancet. Respiratory medicine·2026

Same author

The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammation.

The journal of allergy and clinical immunology. Global·2026

Same author

Educational Intervention on Environmentally Responsible Inhaler Prescribing Among French General Practitioners: Pilot Pre-Post Study.

JMIR formative research·2026

Same author

Complex interplay between disease and aerobic exercise training on vascular function in an exacerbated emphysema rat model.

Journal of applied physiology (Bethesda, Md. : 1985)·2026

Same author

Reply to Zhao et al.: Clarifying Structural - Functional Coupling by FeNO Status in VESTIGE.

American journal of respiratory and critical care medicine·2026

Search research articles

Related Experiment Video

Updated: Jul 9, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Multiple Biologics for Multiple T2 Diseases: A Pharmacoepidemiological Algorithm for Sorting Out Patients by

Jeremy Charriot¹, Vincent Descamps², Roger Jankowski³

¹Department of Respiratory Diseases, University of Montpellier, PhyMedExp, INSERM, CNRS UMR, CHU Montpellier, Montpellier, France.

Journal of Asthma and Allergy

|December 5, 2023

Summary

An algorithm successfully identified patients with Type 2 (T2) diseases, such as severe asthma and atopic dermatitis, receiving biologics (Bx) and targeted synthetic drugs (TSD). This method aids in tracking prescription trends for these advanced therapies.

Keywords:

T2 diseases atopic dermatitis biologics nasal polyposis severe asthma urticaria

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

Related Experiment Videos

Last Updated: Jul 9, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

Area of Science:

Pharmacology
Immunology
Data Science

Background:

Several biologics (Bx) and targeted synthetic drugs (TSD) are available for treating Type 2 (T2) inflammatory diseases.
These conditions include chronic spontaneous urticaria (CSU), severe asthma (SA), chronic rhinosinusitis with nasal polyposis (CRSwNP), and atopic dermatitis (AD).

Purpose of the Study:

To develop and validate an algorithm for identifying patients treated with Bx/TSD using a dynamic dispensing database.
To determine the primary indications for Bx/TSD prescriptions within a real-world setting.

Main Methods:

Utilized the LRx database, covering approximately 45% of French retail pharmacies.
Included patients with at least one Bx/TSD dispensing between April 2021 and March 2022.
Designed a 3-step algorithm analyzing prior drug dispensations since March 2012 to ascertain prescription indications.

Main Results:

The algorithm identified 21,677 patients receiving Bx/TSD, with 91.7% having a confirmed T2 disease indication.
Severe asthma (SA) was the most common reason for Bx/TSD initiation (52%), followed by atopic dermatitis (AD) (29%).
Specific drug patterns emerged, with omalizumab frequently used for SA and dupilumab predominantly for AD.

Conclusions:

The developed algorithm effectively identifies patients with T2 diseases undergoing Bx/TSD treatment.
This methodology offers a valuable tool for monitoring future prescription patterns and treatment evolutions in T2 diseases.